Date: 2018-05-09
Type of information: Grant
Company: IGEM Therapeutics (UK)
Investors: Innovate UK (UK)
Amount: £1.45 million
Funding type: grant
Planned used:
- IGEM will use the award to further the development of IGEM-Ch, a novel IgE antibody targeting solid tumours. IGEM-Ch is a novel and proprietary humanised IgE antibody that binds to the cancer antigen CSPG4 (chondroitin sulphate proteoglycan 4). The CSPG4 antigen is overexpressed in melanoma and various other cancers including triple-negative breast cancer (TNBC). Pre-clinical studies in the laboratory of Dr Sophia Karagiannis at King’s College London demonstrated that an anti-CSPG4 IgE outperformed an equivalent IgG antibody in a variety of challenging models. IGEM has issued patents covering the antibody in the US, Europe and Australia.
Others:
- • On May 9, 2018, IGEM Therapeutics , an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announced the award of a £1.45 million grant from the UK’s innovation agency, Innovate UK. IGEM will use this grant award to further the development of IGEM-Ch. IGEM-Ch is a novel and proprietary humanised IgE antibody that binds to the cancer antigen CSPG4 (chondroitin sulphate proteoglycan 4). The CSPG4 antigen is overexpressed in melanoma and various other cancers including triple-negative breast cancer (TNBC). Pre-clinical studies in the laboratory of Dr Sophia Karagiannis at King’s College London demonstrated that an anti-CSPG4 IgE outperformed an equivalent IgG antibody in a variety of challenging models.
- IGEM will receive £1.02M in net funding from the Biomedical Catalyst award to help progress IGEM-Ch into clinical trials by generation of a pre-clinical development package and efficient GMP manufacturing process.
490
Therapeutic area: Cancer - Oncology
Is general: Yes
